Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients

NCT05611463 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab Plus Docetaxel and Cisplatin

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University